Evolved by Nature vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Activated Silk Biomaterial Platform for Textiles & Personal Care
Evolved by Nature has developed Activated Silk technology — a green chemistry platform using natural silk proteins as sustainable, high-performance ingredients for textiles, personal care, and medical applications; raised over $120M;
About
Evolved by Nature is a Medford, Massachusetts-based biotechnology company founded in 2013 by Gregory Altman and Benedetto Marelli. The company has developed Activated Silk — a liquid silk protein platform that processes natural silk into a water-soluble biopolymer that can be applied as a functional coating or ingredient across multiple industries. Activated Silk is derived from Bombyx mori silkworm cocoons through an aqueous (water-based) process that preserves the protein's native properties without toxic chemicals, yielding a material that is biodegradable, biocompatible, and shelf-stable.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Evolved by Nature vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.